Particularly cells in which very active glucose uptake is critical, e.g. in cancer cells where the reasons for the strong correlation between β2-AR expression and cancer aggressiveness (Cole and Sood, 2012), the frequent involvement of β2-ARs in multiple carcinogenic processes (Perez-Sayans et al., 2012), as well as the beneficial effect of β-AR antagonists on the recovery of cancer patients during chemotherapy (Ji et al., 2012), have remained enigmatic up to now. This evidence concerns the gene ADRB2 and cancer.